At the turn of the 20th century, bovine tuberculosis, a bacterial disease that infected cows and spilled over to humans via milk ran rampant in France. Today, a weakened form of that same ...

Monoclonal antibodies continue to show their ability to rid the brain of amyloid plaques. Trouble is, those antibodies need to be injected on the regular to keep taking down their targets in the brain ...

Epidemiological suggestions that the shingles vaccine might protect against dementia keep rolling in. Pascal Geldsetzer, Stanford University, presented his group’s latest findings at this year’s ...

Is it three steps forward one step back for blood tests? At the 18th Clinical Trials on Alzheimer’s Disease, held December 1–4 in San Diego, new data on the FDA-approved Fujirebio Lumipulse plasma ...

In Pick’s disease, as in Alzheimer’s disease and frontotemporal dementia, tangled tau spells trouble. In this subtype of FTD, abnormal clumps of three-repeat tau called Pick bodies abound in neurons.

Aβ and tau get much of the glory in Alzheimer’s disease, but the disease is far more complex than two proteins. Scientists know, for example, that lipid metabolism goes awry, but identifying ...

This is a knock-in (KI) mouse model carrying a L444P mutation in the endogenous Gba (glucocerebrosidase [GC] or acid β-glucosidase) gene (Liu et al., 1998). The GBA1 protein is the lipid-degrading ...

News Peptide Brace Against AD—Insulin, Neuropeptide Y Tame Aβ Toxicity 10 Feb 2009 Aβ and Phospho-tau: Strange Bedfellows Get Intimate at Synapses 19 Sep 2008 The Skinny on FAT: APP’s Role in Fast ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...